K. M. Hannan

Reduced PAX5 function in mice leads to uncommitted B cell development and B-ALL with secondary mutations in Jak3 and Ptpn11.

This study identifies the nucleolar surveillance pathway (NSP) as a central regulator of p53 stability, showing its role in integrating various cellular stresses and its potential as a therapeutic target in cancer.

The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.

This study identifies that combining RNA Polymerase I inhibitor CX-5461 with TOP1 inhibitor topotecan enhances DNA damage response and efficacy in high-grade serous ovarian cancer.

This study shows that altering PGRMC1 phosphorylation in cancer cells affects energy metabolism, mitochondrial function, and tumor growth.

This study shows CX-5461, an RNA polymerase I inhibitor, enhances PARP inhibitor efficacy in HR-deficient HGSOC by inducing replication stress and DNA damage, overcoming resistance mechanisms.